Johimbin

Johimbin
IUPAC ime
	17α-hidroksi-johimban-16α-; metil estar karboksilne kiseline
Klinički podaci
Prodajno ime	Yocon
Način primene	Oralno
Pravni status
Pravni status	OTC;
Identifikatori
CAS broj	146-48-5
ATC kod	G04BE04 (WHO) QV03AB93
PubChem	CID 8969
IUPHAR/BPS	102
DrugBank	DB01392
ChemSpider	8622
UNII	2Y49VWD90Q
ChEBI	CHEBI:10093
ChEMBL	CHEMBL15245
Hemijski podaci
Formula	C21H26N2O3
Molarna masa	354,44 g/mol (baza); 390,90 g/mol (hidrohlorid)
	SMILES O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O; ;
	InChI InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 ; Key:BLGXFZZNTVWLAY-SCYLSFHTSA-N ;

Johimbin je alkaloid sa stimulantnim i afrodizijskim dejstvom koji se prirodno javlja u biljci Pausinystalia yohimbe. On se takođe prirodno javlja u Rauwolfia serpentina i Alchornea floribunda, zajedno sa nekoliko drugih alkaloida. Johimbin je korišten kao dijetarni suplement u obliku biljnog ekstrakta i kao lek na recepat u čistoj formi za tretman seksualne disfunkcije. Johimbin je izučavan kao lek za tip 2 dijabetes.^[1]

Farmakologija

Johimbin ima visok afinitet za α₂-adrenergički receptor, umereni afinitet za α₁-adrenergički, 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT_1F, 5-HT_2B, i D₂ receptore, i slab afinitet za 5-HT_1E, 5-HT_2A, 5-HT_5A, 5-HT₇, i D₃ receptore.^[2]^[3] On deluje kao antagonist na α₁-adrenergičkom, α₂-adrenergičkom, 5-HT_1B, 5-HT_1D, 5-HT_2A, 5-HT_2B, i D₂, i kao parcijalni agonist na 5-HT_1A.^[2]^[4]^[5]^[6]

Reference

^ Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M.; Tuncel, J. (2009). „Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes”. Science. 327 (5962): 217—20. PMID 19965390. doi:10.1126/science.1176827.
^ ^а ^б Millan MJ; Newman-Tancredi A; Audinot V; et al. (2000). „Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states”. Synapse. 35 (2): 79—95. PMID 10611634. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X.
^ „PDSP Ki Database”. Архивирано из оригинала 8. 11. 2013. г. Приступљено 16. 08. 2012.
^ Arthur JM, Casañas SJ, Raymond JR (1993). „Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors”. Biochemical Pharmacology. 45 (11): 2337—41. PMID 8517875. doi:10.1016/0006-2952(93)90208-E.
^ Kaumann AJ (1983). „Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149—54. PMID 6136920. doi:10.1007/BF00634263.
^ Baxter GS, Murphy OE, Blackburn TP (1994). „Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle”. British Journal of Pharmacology. 112 (1): 323—31. PMC 1910288  . PMID 8032658.

Spoljašnje veze

Yohimbe bark extract

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M.; Tuncel, J. (2009). „Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes”. Science. 327 (5962): 217—20. PMID 19965390. doi:10.1126/science.1176827.

[pmid10611634-2] а ^б Millan MJ; Newman-Tancredi A; Audinot V; et al. (2000). „Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states”. Synapse. 35 (2): 79—95. PMID 10611634. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X.

[urlPDSP_Ki_Database-3] „PDSP Ki Database”. Архивирано из оригинала 8. 11. 2013. г. Приступљено 16. 08. 2012.

[pmid8517875-4] Arthur JM, Casañas SJ, Raymond JR (1993). „Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors”. Biochemical Pharmacology. 45 (11): 2337—41. PMID 8517875. doi:10.1016/0006-2952(93)90208-E.

[pmid6136920-5] Kaumann AJ (1983). „Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149—54. PMID 6136920. doi:10.1007/BF00634263.

[pmid8032658-6] Baxter GS, Murphy OE, Blackburn TP (1994). „Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle”. British Journal of Pharmacology. 112 (1): 323—31. PMC 1910288  . PMID 8032658.

[1]

[2]

[3]

[4]

[5]

[6]

IUPAC ime

17α-hidroksi-johimban-16α- metil estar karboksilne kiseline
Klinički podaci
Prodajno ime	Yocon
Način primene	Oralno
Pravni status
Pravni status	OTC
Identifikatori
CAS broj	146-48-5^Y
ATC kod	G04BE04 (WHO) QV03AB93
PubChem	CID 8969
IUPHAR/BPS	102
DrugBank	DB01392^Y
ChemSpider	8622^Y
UNII	2Y49VWD90Q^Y
ChEBI	CHEBI:10093^Y
ChEMBL	CHEMBL15245^Y
Hemijski podaci
Formula	C₂₁H₂₆N₂O₃
Molarna masa	354,44 g/mol (baza) 390,90 g/mol (hidrohlorid)
SMILES O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O
InChI InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1^Y Key:BLGXFZZNTVWLAY-SCYLSFHTSA-N^Y